Anticancer 'nanoswitch' technology shows promise in animal model of triple-negative breast

Anticancer 'nanoswitch' technology shows promise in animal model of triple-negative breast cancer, colorectal cancer. A research team led by Professor Yoosoo Yang (Department of Integrative Biotechnology) of Sungkyunkwan University, in collaboration with the Korea Institute of Science and Technology (KIST) and Incheon National University, has developed a next-generation anticancer immunotherapy technology that targets and eliminates key substances released by cancer cells while simultaneously boosting the patient's immune response.

A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.

Trechos de apoio da pauta: A research team led by Professor Yoosoo Yang (Department of Integrative Biotechnology) of Sungkyunkwan University, in collaboration with the Korea Institute of Science and Technology (KIST) and Incheon National University, has developed a next-generation anticancer immunotherapy technology that targets and eliminates key substances released by cancer cells while simultaneously boosting the patient's immune response.

• Ponto de atenção: anticancer.
• Ponto de atenção: nanoswitch.
• Ponto de atenção: technology.

Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.